Randomised controlled trial for high-dose intravenous zinc as adjunctive therapy in SARS-CoV-2 (COVID-19) positive critically ill patients: trial protocol.

2020-12-02

Perera, Marlon

El Khoury, John

Chinni, Vidyasagar

Bolton, Damien M

Qu, Liang G

Johnson, Paul D R

Trubiano, Jason

McDonald, Christine F

Jones, Daryl A

Bellomo, Rinaldo

Patel, Oneel

Ischia, Joseph J

infectious diseases

public health

respiratory infections

virology

COVID-19

Journal Article

0000-0002-1138-6389

0000-0002-5111-6367

10.1136/bmjopen-2020-040580

SARS-CoV-2 (COVID-19) has caused an international pandemic of respiratory illness, resulting in significant healthcare and economic turmoil. To date, no robust vaccine or treatment has been identified. Elemental zinc has previously been demonstrated to have beneficial effects on coronaviruses and other viral respiratory infections due to its effect on RNA polymerase. Additionally, zinc has well-demonstrated protective effects against hypoxic injury-a clear mechanism of end-organ injury in respiratory distress syndrome. We aimed to assess the effect of high-dose intravenous zinc (HDIVZn) on SARS-CoV-2 infection. The end of study analyses will evaluate the reduction of impact of oxygen saturations or requirement of oxygen supplementation. We designed a double-blind randomised controlled trial of daily HDIVZn (0.5 mg/kg) versus placebo. Primary outcome measures are lowest oxygen saturation (or greatest level of supplemental oxygenation) for non-ventilated patients and worst PaO2/FiO2 for ventilated patients. Following power calculations, 60 hospitalised patients and 100 ventilated patients will be recruited to demonstrate a 20% difference. The duration of follow-up is up to the point of discharge. Ethical approval was obtained through the independent Human Research Ethics Committee. Participant recruitment will commence in May 2020. Results will be published in peer-reviewed medical journals. ACTRN126200000454976.

link

BMJ open 2020; 10(12): e040580

BMJ open